NASDAQ:AMPH

Amphastar Pharmaceuticals Stock Forecast, Price & News

$20.85
-0.05 (-0.24 %)
(As of 07/29/2021 01:20 PM ET)
Add
Compare
Today's Range
$20.70
$20.91
50-Day Range
$18.66
$20.92
52-Week Range
$16.91
$21.38
Volume325 shs
Average Volume206,997 shs
Market Capitalization$993.19 million
P/E Ratio417.00
Dividend YieldN/A
Beta0.73
30 days | 90 days | 365 days | Advanced Chart
Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Amphastar Pharmaceuticals logo

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

544th out of 2,215 stocks

Pharmaceutical Preparations Industry

273rd out of 869 stocks

Analyst Opinion: 1.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

Is Amphastar Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Amphastar Pharmaceuticals?

Wall Street analysts have given Amphastar Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amphastar Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amphastar Pharmaceuticals
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings data on Thursday, May, 6th. The company reported $0.27 EPS for the quarter, topping the Zacks' consensus estimate of $0.19 by $0.08. The company earned $103.02 million during the quarter, compared to analyst estimates of $97.12 million. Amphastar Pharmaceuticals had a net margin of 0.68% and a trailing twelve-month return on equity of 7.45%.
View Amphastar Pharmaceuticals' earnings history
.

How has Amphastar Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Amphastar Pharmaceuticals' stock was trading at $15.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMPH shares have increased by 36.3% and is now trading at $20.85.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AMPH?

2 brokers have issued twelve-month target prices for Amphastar Pharmaceuticals' shares. Their forecasts range from $20.00 to $23.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:
  • Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 71, Pay $1.23M)
  • Dr. Yongfeng Zhang, Co-founder, Pres, CEO, Chief Scientific Officer & Director (Age 74, Pay $1.98M)
  • Mr. William J. Peters, CFO, Treasurer & Exec. VP of Fin. (Age 53, Pay $1.09M) (LinkedIn Profile)
  • Mr. Jacob Liawatidewi M.B.A., Exec. VP of Corp. Admin. Center, Sales & Marketing and Corp. Sec. (Age 47, Pay $749.57k)
  • Mr. Rong Zhou, Exec. VP of Production Center (Age 62, Pay $768.66k) (LinkedIn Profile)
  • Dan Dischner, VP of Corp. Communications
  • Tony Marrs, Sr. VP of Regulatory Affairs and Clinical Operations
  • Mr. Peter Langosh, VP of Operational Improvement and VP of Internal Audit (Age 68)

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amphastar Pharmaceuticals' key competitors?

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.05%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals
.

Which major investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Amphastar Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $20.85.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals has a market capitalization of $993.19 million and generates $349.85 million in revenue each year. The company earns $1.40 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,980 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

Where are Amphastar Pharmaceuticals' headquarters?

Amphastar Pharmaceuticals is headquartered at 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.